23 September 2019

Meet us at BIO-Europe 2019, Nov. 11 & 12
23 September 2019

OREGA Biotech – meet us at BIO-Europe 2019, Nov. 11 & 12  Lyon, France, September 23, 2019 – OREGA Biotech will participate in the upcoming BIO-Europe conference to be held in Hamburg, Germany, on November 11-13, 2019. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. OREGA Biotech will actively take part in this business event to promote our partnership-driven business model based on our in vivo screening platform aiming at discovering novel immune checkpoints and regulators of anti-PD1 response. Building on the successful partnering of our anti-CD39 antibodies (licensed to Innate Pharma and now partnered with AstraZeneca), we are open to discussion for our new program related to the discovery of a novel regulator of anti-PD1 response. Jeremy Bastid, Chief Operating Officer, will attend the BIO-Europe conference on November 11 & 12, 2019. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoints and regulators of anti-PD1 response. Anti-CD39 antibody were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with our targets prior entering into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO. For more information: www.orega-biotech.com  
[ Read more ]
17 September 2019

Dr Bonnefoy to inaugurate first CyTOF Hyperion in France
17 September 2019

Nathalie Bonnefoy, cofounder of OREGA Biotech and deputy director of Institut de Recherche en Cancérologie de Montpellier (IRCM), will inaugurate the first CyTOF Hyperion in France on September 18, 2019 at IRCM. Equipped with a very innovative technology, the CyTOF Hyperion will make it possible to explore tumor heterogeneity from a biopsy by very finely mapping tumor cells in their microenvironment, including the interactions with and between the immune cells. The CyTOF is a powerful tool for immuno-oncology studies. It reveals the structure of disease tissue at the single cell level and enables the characterization with up to 50 markers, from a single slide, of the spatial distribution and the cellular network with immune cells.
[ Read more ]
27 July 2019

Anti-CD39 mAb publication in Cell Reports
27 July 2019

The publication of preclinical data of the CD39-blocking monoclonal antibody IPH5201 appears in the May 21, 2019 issue of the journal Cell Reports.  Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies”
[ Read more ]
17 June 2019

Meet us at the 2019 ASCO annual meeting in Chicago
17 June 2019

Jeremy BASTID, Chief Operating Officer, will attend the ASCO annual meeting to be held in Chicago, IL, May 31 – June 4, 2019.
[ Read more ]